Table 3.

Multivariate analysis of LLT use by participant characteristics

	Relative RR
	High‐Intensity Statin vs No Current	Moderate‐Intensity Statin vs No Current	Low‐Intensity Statin vs No Current	Nonstatin LLT vs No Current
Demographic characteristics
Age categories, y
20–39	Ref	Ref	Ref	Ref
40–49	2.85	2.66	2.23	2.47
50–59	4.79	4.29	3.23	4.76
60–69	5.55	5.35	4.31	5.91
70–79	4.03	5.22	4.97	5.17
≥80	2.04	3.99	4.62	3.52
Male sex	1.41	1.14	0.97	0.92
Region
South	Ref	Ref	Ref	Ref
Northeast	0.97	1.07	0.97	0.82
Midwest	1.22	1.10	1.08	0.94
West/other	1.14	1.05	1.07	0.89
Baseline clinical characteristics
Recent ACS	1.69	0.94	0.84	0.62
Other CHD	2.02	1.17	0.91	1.30
Ischemic stroke	1.15	1.09	1.13	0.91
PAD	1.06	0.99	0.99	1.09
DM	1.17	1.29	1.31	1.34
HTN	1.26	1.23	1.20	1.33
History of CHF	0.70	0.74	0.82	0.72
CKD
No CKD	Ref	Ref	Ref	Ref
Stage III	1.12	1.09	1.11	1.12
Stage IV–V 1	0.91	0.95	1.10	0.94
Dementia	0.56	0.75	0.94	0.70
COPD	0.86	0.94	1.01	0.99
MSK pain, % 2	0.86	0.92	0.98	1.23
Moderate/severe liver disease	0.25	0.35	0.50	1.19
Concomitant medication use 3
β‐Blockers	3.00	2.39	2.15	2.22
ACEIs/ARBs	2.73	2.56	2.66	2.06
Antiplatelets, % 4	4.20	2.77	2.13	2.78

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; LLT, lipid‐lowering therapy; MSK, musculoskeletal; PAD, peripheral arterial disease; Ref, reference; RR, risk ratio.

Overall P values for each covariate were <0.001.

¹Includes dialysis.

²Diagnosis associated with MSK pain.

³Filled medications on index date.

⁴Clopidogrel, ticagrelor, prasugrel.